Endoscopic submucosal dissection for papillary early gastric carcinoma: Insights from a large-scale analysis of post-gastrectomy pathology specimens

Jung Hwan Lee,Ju Yeon Oh,Young-Il Kim,Jong Yeul Lee,Chan Gyoo Kim,Il Ju Choi,Keun Won Ryu,Young-Woo Kim,Soo-Jeong Cho
DOI: https://doi.org/10.1097/md.0000000000032085
IF: 1.6
2022-12-23
Medicine
Abstract:Endoscopic submucosal dissection (ESD) is a standard treatment for limited-stage early gastric cancer (EGC). [ 1 ] It has benefits of being minimally invasive, yielding higher rates of both en bloc and complete resection than endoscopic mucosal resection. [ 2 ] However, it is important to evaluate the risk of lymph node metastasis of EGC before performing an ESD. Indications for ESD have been based on reports that certain groups of patients with EGC have a minimal risk or no likelihood of developing lymph node metastasis, thereby shifting the risk-benefit ratio in favor of ESD. [ 3 ] Current indication criteria include differentiated tumors with minimal submucosal invasion or ulceration, although some oncology societies have expanded their criteria to include undifferentiated EGCs without submucosal invasion and differentiated tumors with minimal invasion or with ulcers but no invasion. [ 4–6 ]
medicine, general & internal
What problem does this paper attempt to address?